Mitsubishi Tanabe Pharma operates commercial subsidiaries in Europe, the U.S., Korea and beyond, as well as a manufacturing facility in Indonesia, according to its various websites. The company ...

TOKYO & BOSTON--(BUSINESS WIRE)--Bain Capital, a leading global private investment firm, today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation ...

US private equity firm Bain Capital has agreed to acquire Mitsubishi Chemical Group’s pharmaceutical unit Mitsubishi Tanabe Pharma in a deal valued at approximately Y510bn ($3.3bn). The ...

Bain Capital, an investment firm that has spread its life sciences bets mainly across companies developing novel new medicines, is acquiring Mitsubishi Tanabe Pharma Corporation in a multi-billion ...

The deal values Mitsubishi Tanabe Pharma at about ¥510 billion ($3.3 billion), according to a statement on Friday. The transaction is expected to be completed in the third quarter, pending ...

TOKYO :U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of regulatory change for ...

MTPC employs over 5,000 people globally. As an independent company, Tanabe Pharma will continue to build on its legacy of medical innovation while developing new opportunities for growth through ...

US investment group Bain Capital has agreed to buy Mitsubishi Tanabe Pharma for JPY 510 billion (around $3.4 billion), setting up one of the largest private equity buyouts in Japan's healthcare ...

the pharma arm of Mitsubishi Chemical Group Corporation. The deal puts Tanabe Pharma at a valuation of about $3.3 billion. Founded in 1678, Tanabe Pharma is headquartered in Doshomachi ...

TOKYO, Feb 7 (Reuters) - U.S. private equity firm Bain Capital has bought Mitsubishi Tanabe Pharma in a deal worth 510 billion yen ($3.4 billion), saying it was encouraged by prospects of ...

today announced it has signed a definitive agreement to acquire Mitsubishi Tanabe Pharma Corporation (“Tanabe Pharma”, “MTPC” or “the Company”) in a carve-out transaction from ...

The U.S. investment company is in the final stages of negotiations to buy the subsidiary, Mitsubishi Tanabe Pharma, for possibly more than 500 billion yen, equivalent to $3.21 billion, the person ...